Guardant Health Japan receives regulatory approval of Guardant360® CDx liquid biopsy as companion diagnostic for amivantamab-vmjw to identify patients with inoperable or recurrent NSCLC harbouring EGFR exon 20 insertion mutations, Business News
Business new tamfitronics Guardant360® CDxis the first blood-based companion diagnostic to be approved in Japan for the detection of EGFR exon 20 insertion mutations /PRNewswire/ — Guardant Health Japan Corp. (HQ: Minato-ku, Tokyo/ Representative Director: Mika Takaki), a leading precision oncology company, today announced that the Ministry of Health, Labour and Welfare (MHLW) in Japan has […]